Arrowhead Pharmaceuticals, Inc.
ARWR
$65.09
$0.020.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -29.60% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -29.60% | -100.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -29.60% | -100.00% |
| SG&A Expenses | 45.80% | 21.28% | 13.40% | 12.16% | -12.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.93% | 9.75% | 27.99% | 17.00% | 30.36% |
| Operating Income | 127.19% | 6.01% | 402.08% | -18.21% | -49.73% |
| Income Before Tax | 120.90% | -2.94% | 391.05% | -26.26% | -58.54% |
| Income Tax Expenses | 3,563.00% | -- | -- | 103.11% | -73.04% |
| Earnings from Continuing Operations | 109.30% | -2.69% | 389.67% | -29.43% | -56.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1,519.91% | 7.13% | 52.24% | -15.09% | 110.18% |
| Net Income | 86.07% | -2.60% | 395.65% | -30.27% | -55.49% |
| EBIT | 127.19% | 6.01% | 402.08% | -18.21% | -49.73% |
| EBITDA | 132.12% | 7.02% | 418.32% | -18.06% | -50.45% |
| EPS Basic | 87.44% | 8.35% | 373.31% | -12.09% | -34.06% |
| Normalized Basic EPS | 85.18% | 8.17% | 377.99% | -9.70% | -35.80% |
| EPS Diluted | 87.30% | 8.67% | 369.61% | -12.10% | -34.06% |
| Normalized Diluted EPS | 85.18% | 8.17% | 375.67% | -9.70% | -35.80% |
| Average Basic Shares Outstanding | 10.87% | 11.95% | 8.17% | 16.23% | 15.99% |
| Average Diluted Shares Outstanding | 10.87% | 11.95% | 9.08% | 16.23% | 15.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |